Plasma Exchange Shows Promise for Treating Sepsis and Septic Shock
Comprehensive review reveals therapeutic plasma exchange may improve survival and organ function in sepsis patients through multiple mechanisms.
Summary
This narrative review examines therapeutic plasma exchange (TPE) as an adjunctive treatment for sepsis and septic shock. TPE works by removing harmful inflammatory substances while replenishing essential plasma components. Current evidence from small studies suggests TPE may improve hemodynamics, reduce vasopressor requirements, and potentially decrease mortality. However, most data comes from retrospective studies and small randomized trials, limiting definitive conclusions about efficacy.
Detailed Summary
Sepsis remains a leading cause of ICU mortality despite treatment advances, affecting nearly 49 million people annually with 11 million deaths worldwide. This comprehensive review evaluates therapeutic plasma exchange (TPE) as a promising adjunctive therapy for sepsis and septic shock management.
TPE operates through dual mechanisms: removing harmful mediators and replenishing essential plasma components. The treatment clears inflammatory cytokines, improves thrombotic microangiopathy, regulates immune imbalance, and enhances vascular endothelial function. Unlike conventional blood purification methods that primarily target small molecules, TPE can remove larger inflammatory mediators and endotoxins while restoring critical factors like ADAMTS13 and anticoagulant proteins.
Current evidence shows encouraging but limited results. Several small randomized controlled trials and retrospective studies suggest TPE may reduce 28-day mortality, improve hemodynamic stability, and decrease vasopressor requirements. One notable study of 106 adults with septic shock found a 20.5% reduction in 28-day mortality with TPE compared to standard care. Meta-analyses incorporating nearly 1,000 patients with sepsis-induced organ dysfunction showed significant reductions in short-term mortality.
However, the evidence remains inconclusive due to study limitations. Most data derives from retrospective analyses and small-scale trials, with conflicting results in some studies. The American Society for Apheresis classifies TPE as a category III intervention for sepsis with multiple organ failure, reflecting uncertain therapeutic benefit. Current guidelines offer only cautious recommendations for TPE use.
Future research requires larger randomized controlled trials to establish definitive evidence for TPE's role in sepsis management, particularly regarding optimal timing, patient selection, and treatment protocols.
Key Findings
- TPE may reduce 28-day mortality by 20.5% in septic shock patients compared to standard care
- Treatment rapidly improves hemodynamics and reduces norepinephrine requirements within 6 hours
- TPE effectively clears inflammatory cytokines including IL-6 and IL-8 while replenishing protective factors
- Meta-analysis of 937 patients showed significant reduction in short-term mortality with TPE
- Current evidence remains limited to small studies and retrospective analyses
Methodology
This narrative review follows SANRA guidelines and synthesizes evidence from retrospective studies, small randomized controlled trials, and meta-analyses examining TPE in sepsis and septic shock patients across pediatric and adult populations.
Study Limitations
Most evidence derives from retrospective studies and small randomized trials with heterogeneous patient populations. Conflicting results exist, and optimal timing, patient selection criteria, and treatment protocols remain undefined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.